Ordinarily, a report of zero revenue in a quarter would not be too well received by investors. That was exactly the top-line result for Cara Therapeutics (NASDAQ:CARA) when the company reported first-quarter results on May 9, and while the stock did take a minor hit on the announcement, the important news for this clinical-stage biotech had nothing to do with the numbers.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,